Shopping Cart 0
Cart Subtotal
AED 0

ProQR Therapeutics NV (PRQR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company's lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It develops novel investigational drug called QR-421 for the treatment of usher syndrome, fuchs endothelial corneal dystrophy, dystrophic epidermolysis bullosa, alzheimer's disease, central nervous system and neuromuscular diseases. The company also offers clinical trial services. It operates through its laboratory and offices located in Leiden. It operates offices in the US and the Netherlands. ProQR is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NV (PRQR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11

Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12

ProQR Therapeutics and Galapagos Enter into Research Agreeement 13

Licensing Agreements 14

ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14

ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15

ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16

ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18

Equity Offering 19

ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19

Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21

Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22

Amylon Therapeutics Spin Out from ProQR Therapeutics 23

ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24

ProQR Therapeutics Raises USD112 Million in IPO 25

ProQR Therapeutics NV-Key Competitors 27

ProQR Therapeutics NV-Key Employees 28

ProQR Therapeutics NV-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Strategy And Business Planning 30

Sep 12, 2017: ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics 30

Financial Announcements 31

Aug 08, 2018: ProQR announces financial results for the second quarter of 2018 31

May 09, 2018: ProQR Announces Results for the First Quarter of 2018 32

Feb 28, 2018: ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update 34

Nov 20, 2017: ProQR Announces Results for the Third Quarter of 2017 37

Aug 16, 2017: ProQR Announces Results for the Second Quarter of 2017 39

May 17, 2017: ProQR Announces Results for the First Quarter of 2017 41

Feb 28, 2017: ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update 43

Corporate Communications 46

May 23, 2018: ProQR Appoints Yi-Tao Yu to Its Scientific Advisory Board 46

Nov 09, 2017: ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board 47

Oct 26, 2017: ProQR Announces Management Change and Key Promotions 48

Aug 28, 2017: ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong 49

Mar 27, 2017: ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer 50

Product News 51

Jun 15, 2017: ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer, a novel proprietary RNA Technology 51

05/01/2017: ProQR to Present Data on QRX-411 at ARVO 53

05/01/2017: ProQR to Present Data on QRX-421 at ARVO 54

Product Approvals 55

Sep 05, 2017: ProQR's Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 55

Jul 05, 2017: ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 56

Clinical Trials 57

Oct 24, 2017: ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference 57

Sep 25, 2017: ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis 58

Aug 29, 2017: ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial 60

Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ProQR Therapeutics NV, Deals By Therapy Area, 2012 to YTD 2018 9

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11

Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12

ProQR Therapeutics and Galapagos Enter into Research Agreeement 13

ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14

ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15

ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16

ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18

ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19

Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21

Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22

Amylon Therapeutics Spin Out from ProQR Therapeutics 23

ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24

ProQR Therapeutics Raises USD112 Million in IPO 25

ProQR Therapeutics NV, Key Competitors 27

ProQR Therapeutics NV, Key Employees 28

ProQR Therapeutics NV, Other Locations 29

ProQR Therapeutics NV, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ProQR Therapeutics NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company's lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It develops novel investigational drug called QR-421 for the treatment of usher syndrome, fuchs endothelial corneal dystrophy, dystrophic epidermolysis bullosa, alzheimer's disease, central nervous system and neuromuscular diseases. The company also offers clinical trial services. It operates through its laboratory and offices located in Leiden. It operates offices in the US and the Netherlands. ProQR is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NV (PRQR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11

Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12

ProQR Therapeutics and Galapagos Enter into Research Agreeement 13

Licensing Agreements 14

ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14

ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15

ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16

ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18

Equity Offering 19

ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19

Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21

Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22

Amylon Therapeutics Spin Out from ProQR Therapeutics 23

ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24

ProQR Therapeutics Raises USD112 Million in IPO 25

ProQR Therapeutics NV-Key Competitors 27

ProQR Therapeutics NV-Key Employees 28

ProQR Therapeutics NV-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Strategy And Business Planning 30

Sep 12, 2017: ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics 30

Financial Announcements 31

Aug 08, 2018: ProQR announces financial results for the second quarter of 2018 31

May 09, 2018: ProQR Announces Results for the First Quarter of 2018 32

Feb 28, 2018: ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update 34

Nov 20, 2017: ProQR Announces Results for the Third Quarter of 2017 37

Aug 16, 2017: ProQR Announces Results for the Second Quarter of 2017 39

May 17, 2017: ProQR Announces Results for the First Quarter of 2017 41

Feb 28, 2017: ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update 43

Corporate Communications 46

May 23, 2018: ProQR Appoints Yi-Tao Yu to Its Scientific Advisory Board 46

Nov 09, 2017: ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board 47

Oct 26, 2017: ProQR Announces Management Change and Key Promotions 48

Aug 28, 2017: ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong 49

Mar 27, 2017: ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer 50

Product News 51

Jun 15, 2017: ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer, a novel proprietary RNA Technology 51

05/01/2017: ProQR to Present Data on QRX-411 at ARVO 53

05/01/2017: ProQR to Present Data on QRX-421 at ARVO 54

Product Approvals 55

Sep 05, 2017: ProQR's Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 55

Jul 05, 2017: ProQR's Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 56

Clinical Trials 57

Oct 24, 2017: ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference 57

Sep 25, 2017: ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis 58

Aug 29, 2017: ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial 60

Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

ProQR Therapeutics NV, Deals By Therapy Area, 2012 to YTD 2018 9

ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11

Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12

ProQR Therapeutics and Galapagos Enter into Research Agreeement 13

ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14

ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15

ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16

ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17

ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18

ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19

Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21

Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22

Amylon Therapeutics Spin Out from ProQR Therapeutics 23

ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24

ProQR Therapeutics Raises USD112 Million in IPO 25

ProQR Therapeutics NV, Key Competitors 27

ProQR Therapeutics NV, Key Employees 28

ProQR Therapeutics NV, Other Locations 29

ProQR Therapeutics NV, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ProQR Therapeutics NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.